A Phase 1 interventional study of Phenylephrine in Blood Loss, Surgical, sponsored by University of Manitoba. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by University of Manitoba · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Blood Loss, Surgical with a site in Canada — 5 open to participants now, 6 under way, 2 of them phase 3. Blood Loss, Surgical · Canada.
Among the 21 studies in Blood Loss, Surgical with a site in Canada, this one is the 17th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2014, is the only one in phase 1, and was the 9th registered.
213 studies on the registry are indexed under Blood Loss, Surgical; 40 are open to participants now.
Browse Blood Loss, Surgical studies →5 of the 21 studies in Blood Loss, Surgical with a site in Canada are open now. Recruiting first, the newest first:
VarmX B.V. · Sites in Canada, United States, Australia and 17 more countries
Ages 18+
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
Dr. Glenio Mizubuti (MD, PhD, FRCPC) · Sites in Canada
Ages 18+
Hamilton Health Sciences Corporation · Sites in Canada
Ages 18–100
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 27 Blood Loss, Surgical studies recruiting now, 10 (37%) set no upper age limit and 14 (52%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 80 across 160 interventional studies indexed under Blood Loss, Surgical.
Median enrollment 125 across the 17 interventional studies, 80 across the 4 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 21 have an industry lead sponsor. The 10 most frequent:
University of Manitoba is the lead sponsor of 555 studies on the registry; 89 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.
University of Manitoba has 1 study filed under Blood Loss, Surgical — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Blood Loss, Surgical with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The standard of care for treatment of burn injury is to inject a solution of epinephrine under the skin of the injured site in order to reduce blood loss during skin grafting. This solution of epinephrine has been shown to have effects on the body outside the donor site. Some people have increases in heart rate and blood pressure. We will study the effect of a phenylephrine solution in place of an epinephrine solution to control blood loss. We think that phenylephrine will help decrease blood loss and not change blood pressure or heart rate.
The injured area will be injected under the skin and a skin graft will be taken in the same way as we usually do. The only change will be the use of phenylephrine in the solution instead of epinephrine.
Our goal is to find whether or not phenylephrine or epinephrine solution results in a reduction of blood loss without affecting the rest of the body.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
a) Burn injury requiring debridement and grafting between 5-30% TBSA
Exclusion Criteria
20 ug/cc
Drug: Phenylephrine
1:1000000
Drug: Phenylephrine
Mean arterial blood pressure (MAP)
Mean arterial blood pressure
Time frame: during first 30 minutes
Blood Pressure
Cut off for safety: Diastolic \>140 or Systolic \>180; Recorded: * just prior to induction of anesthesia * maximum heart rate during time of procedure * minimum heart rate during time of procedure
Time frame: q15 min
Heart Rate
Recorded: * just prior to induction of anesthesia * maximum heart rate during time of procedure * minimum heart rate during time of procedure
Time frame: q15 min
Started Dec 2014 (actual). Primary completion is estimated for Jun 2028, 162 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phenylephrine